356 related articles for article (PubMed ID: 30740725)
1. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R; Péanne R; Jaeken J; Barone R; Bidet M; Borgel D; Brasil S; Cassiman D; Cechova A; Coman D; Corral J; Correia J; de la Morena-Barrio ME; de Lonlay P; Dos Reis V; Ferreira CR; Fiumara A; Francisco R; Freeze H; Funke S; Gardeitchik T; Gert M; Girad M; Giros M; Grünewald S; Hernández-Caselles T; Honzik T; Hutter M; Krasnewich D; Lam C; Lee J; Lefeber D; Marques-de-Silva D; Martinez AF; Moravej H; Õunap K; Pascoal C; Pascreau T; Patterson M; Quelhas D; Raymond K; Sarkhail P; Schiff M; Seroczyńska M; Serrano M; Seta N; Sykut-Cegielska J; Thiel C; Tort F; Vals MA; Videira P; Witters P; Zeevaert R; Morava E
J Inherit Metab Dis; 2019 Jan; 42(1):5-28. PubMed ID: 30740725
[TBL] [Abstract][Full Text] [Related]
2. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).
Martínez-Monseny AF; Bolasell M; Callejón-Póo L; Cuadras D; Freniche V; Itzep DC; Gassiot S; Arango P; Casas-Alba D; de la Morena E; Corral J; Montero R; Pérez-Cerdá C; Pérez B; Artuch R; Jaeken J; Serrano M;
Ann Neurol; 2019 May; 85(5):740-751. PubMed ID: 30873657
[TBL] [Abstract][Full Text] [Related]
3. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
4. Unsuccessful intravenous D-mannose treatment in PMM2-CDG.
Grünert SC; Marquardt T; Lausch E; Fuchs H; Thiel C; Sutter M; Schumann A; Hannibal L; Spiekerkoetter U
Orphanet J Rare Dis; 2019 Oct; 14(1):231. PubMed ID: 31640729
[TBL] [Abstract][Full Text] [Related]
5. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
[TBL] [Abstract][Full Text] [Related]
6. Initial diagnosis of the congenital disorder of glycosylation PMM2-CDG (CDG1a) in a 4-year-old girl after neurosurgical intervention for cerebral hemorrhage.
Stefanits H; Konstantopoulou V; Kuess M; Milenkovic I; Matula C
J Neurosurg Pediatr; 2014 Nov; 14(5):546-9. PubMed ID: 25192236
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
8. [Congenital disorder of glycosylation type Ia (CDG Ia) - underdiagnosed entity?].
Sätilä H; Kuusela AL; Pietilä K; Niinikoski H; Keskinen P
Duodecim; 2016; 132(3):253-9. PubMed ID: 26951030
[TBL] [Abstract][Full Text] [Related]
9. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.
Monin ML; Mignot C; De Lonlay P; Héron B; Masurel A; Mathieu-Dramard M; Lenaerts C; Thauvin C; Gérard M; Roze E; Jacquette A; Charles P; de Baracé C; Drouin-Garraud V; Khau Van Kien P; Cormier-Daire V; Mayer M; Ogier H; Brice A; Seta N; Héron D
Orphanet J Rare Dis; 2014 Dec; 9():207. PubMed ID: 25497157
[TBL] [Abstract][Full Text] [Related]
10. Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
Muthusamy K; Perez-Ortiz JM; Ligezka AN; Altassan R; Johnsen C; Schultz MJ; Patterson MC; Morava E
Genet Med; 2024 Feb; 26(2):101027. PubMed ID: 37955240
[TBL] [Abstract][Full Text] [Related]
11. Renal involvement in PMM2-CDG, a mini-review.
Altassan R; Witters P; Saifudeen Z; Quelhas D; Jaeken J; Levtchenko E; Cassiman D; Morava E
Mol Genet Metab; 2018 Mar; 123(3):292-296. PubMed ID: 29229467
[TBL] [Abstract][Full Text] [Related]
12. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
13. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
14. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
[TBL] [Abstract][Full Text] [Related]
15. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
[TBL] [Abstract][Full Text] [Related]
16. Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).
Taday R; Grüneberg M; DuChesne I; Reunert J; Marquardt T
Orphanet J Rare Dis; 2020 Sep; 15(1):258. PubMed ID: 32962735
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
Budhraja R; Radenkovic S; Jain A; Muffels IJJ; Ismaili MHA; Kozicz T; Pandey A; Morava E
Mol Genet Metab; 2024 Jun; 142(2):108487. PubMed ID: 38733638
[TBL] [Abstract][Full Text] [Related]
18. The Analysis of Variants in the General Population Reveals That
Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
[TBL] [Abstract][Full Text] [Related]
19. New and potential strategies for the treatment of PMM2-CDG.
Gámez A; Serrano M; Gallego D; Vilas A; Pérez B
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129686. PubMed ID: 32712172
[TBL] [Abstract][Full Text] [Related]
20. Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals.
Pascoal C; Ferreira I; Teixeira C; Almeida E; Slade A; Brasil S; Francisco R; Ligezka AN; Morava E; Plotkin H; Jaeken J; Videira PA; Barros L; Dos Reis Ferreira V
Orphanet J Rare Dis; 2022 Oct; 17(1):398. PubMed ID: 36309700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
